Zim Laboratories Ltd
Incorporated in 1989, Zim Laboratories
Ltd manufactures formulation drugs and
pre formulation ingredients in India and
markets and sells these within and out
side India[1]
- Market Cap ₹ 450 Cr.
- Current Price ₹ 92.4
- High / Low ₹ 153 / 74.0
- Stock P/E 27.5
- Book Value ₹ 46.4
- Dividend Yield 0.00 %
- ROCE 16.6 %
- ROE 13.0 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 7.88% over past five years.
- Promoter holding is low: 33.3%
- Company has a low return on equity of 9.74% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|
266 | 269 | 235 | 273 | 335 | 278 | 307 | 333 | 399 | 355 | |
278 | 239 | 203 | 238 | 293 | 255 | 268 | 292 | 347 | 314 | |
Operating Profit | -12 | 30 | 32 | 35 | 42 | 23 | 40 | 41 | 52 | 41 |
OPM % | -4% | 11% | 13% | 13% | 13% | 8% | 13% | 12% | 13% | 12% |
2 | -2 | 5 | 9 | 2 | 5 | -3 | 4 | 6 | 4 | |
Interest | 10 | 14 | 10 | 9 | 11 | 13 | 11 | 8 | 6 | 6 |
Depreciation | 7 | 9 | 9 | 10 | 11 | 14 | 16 | 16 | 17 | 17 |
Profit before tax | -27 | 5 | 18 | 25 | 22 | 0 | 10 | 21 | 35 | 23 |
Tax % | 19% | 5% | -6% | 23% | 30% | -4,600% | 28% | 31% | 31% | |
-22 | 5 | 19 | 19 | 15 | 3 | 7 | 15 | 24 | 16 | |
EPS in Rs | 3.17 | 0.68 | 1.50 | 2.99 | 5.01 | 3.37 | ||||
Dividend Payout % | 0% | 16% | 4% | 4% | 5% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 8% |
3 Years: | 13% |
TTM: | -11% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 10% |
3 Years: | 95% |
TTM: | -32% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 17% |
3 Years: | 55% |
1 Year: | 9% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 9% |
3 Years: | 10% |
Last Year: | 13% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 8 | 8 | 8 | 8 | 16 | 16 | 16 | 16 | 49 | 49 |
Reserves | 86 | 91 | 110 | 129 | 135 | 138 | 145 | 159 | 152 | 177 |
93 | 96 | 81 | 81 | 77 | 90 | 82 | 53 | 62 | 62 | |
78 | 61 | 60 | 81 | 100 | 82 | 82 | 112 | 79 | 78 | |
Total Liabilities | 265 | 256 | 259 | 298 | 328 | 325 | 325 | 342 | 342 | 366 |
87 | 92 | 89 | 94 | 106 | 116 | 107 | 106 | 109 | 121 | |
CWIP | 6 | 3 | 4 | 8 | 13 | 10 | 11 | 12 | 27 | 41 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
172 | 161 | 166 | 196 | 209 | 200 | 208 | 224 | 206 | 204 | |
Total Assets | 265 | 256 | 259 | 298 | 328 | 325 | 325 | 342 | 342 | 366 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|
22 | 32 | 37 | 35 | 22 | 32 | 49 | 38 | ||
-12 | -7 | -26 | -21 | -19 | -6 | -14 | -35 | ||
-10 | -25 | -10 | -15 | -2 | -26 | -33 | 1 | ||
Net Cash Flow | -0 | -0 | 1 | -1 | 1 | -0 | 2 | 3 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|
Debtor Days | 111 | 120 | 137 | 119 | 101 | 89 | 86 | 98 | 87 |
Inventory Days | 93 | 87 | 108 | 134 | 126 | 144 | 125 | 171 | 99 |
Days Payable | 129 | 109 | 137 | 172 | 165 | 168 | 149 | 185 | 107 |
Cash Conversion Cycle | 75 | 99 | 108 | 81 | 63 | 65 | 62 | 85 | 79 |
Working Capital Days | 108 | 111 | 127 | 104 | 83 | 111 | 121 | 104 | 100 |
ROCE % | 13% | 14% | 14% | 15% | 5% | 11% | 12% | 17% |
Documents
Announcements
- Intimation For Grant Of Employee Stock Options Under 'ZIM Laboratories Employee Stock Option Scheme 2023' 13 Apr
-
Compliance Certificate Under Regulation 40(9) Of SEBI (LODR) Regulations, 2015.
12 Apr - Certificate under Regulation 40(9) by Practicing Company Secretaries - Mehta & Mehta
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 9 Apr
-
Announcement under Regulation 30 (LODR)-Credit Rating
6 Apr - CARE Ratings Limited had reaffirmed the ratings on the bank facilities of the Company.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
5 Apr - Compliance Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the Quarter ended March 31, 2024.
Annual reports
Concalls
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023TranscriptNotesPPT
-
Feb 2019TranscriptNotesPPT
-
Dec 2018TranscriptNotesPPT
Business Overview:[1]
ZLL is a EU-GMP, WHOGMP, NSF/ANSI 455-2 certified research-driven pharmaceutical company that develops, manufactures and supplies generic products in the oral solid dosage forms, both as pre-formulation intermediates ad finished formulations for certain key therapeutic segments. It offers both pharmaceutical and nutraceutical products. Company has an in-house R&D capabilities to offer a range of non-infringing drug
delivery solutions based on process technologies